Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocularis Pharma Inc.

Latest From Ocularis Pharma Inc.

Start-Up Previews (2/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Rediscovering Existing Drugs, features profiles of Ascend Therapeutics Inc., Ocularis Pharma Inc. and Oriel Therapeutics Inc. Plus these Start-Ups Across Health Care: Exagen Diagnostics Inc., Piedmont Pharmaceuticals LLC, Protein Forest Inc., Proteus Biomedical Inc. and Xilas Medical Inc.

Rediscovering Existing Drugs

There's been a lot of talk lately about unlocking the hidden value from existing products, that is, drugs that have gone all the way from pure discovery, through the FDA regulatory process and into the hands of patients. These are the industry's greatest assets; they've already distinguished themselves from millions of other compounds by passing the myriad tests related to disease relevancy, safety, efficacy, and more safety, since safety isn't ultimately known until drugs disseminate through the treatment population, years after approval. Recently, there's been a shift to applying the industrial revolution in de novo drug discovery--the tools for screening and assaying libraries of random compounds-to existing drugs, as companies look for new products by reprofiling, repurposing, and redirecting the development of old drugs.
BioPharmaceutical Business Strategies

Ocularis Pharma Inc.

Ocularis has found a simple solution-a drug delivered in the form of eyedrops-for the problem of impaired night vision. Poor night vision is a generally unrecognized and largely unstudied phenomenon, but it affects every fourth person, the company believes. Because it's working with a new formulation of an already-approved drug that's available in an injectable formulation for a different indication, it's been able to move quickly into clinical trials.
BioPharmaceutical Business Strategies

Selected Start-Ups (4/03)

In Vivo briefly summarizes the technologies of these recently founded companies: AdvanDx Inc., AngioDesign Inc., Chiasma Inc., Ocularis Pharma Inc., Trism Inc. and Zelos Therapeutics Inc.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ocularis Pharma Inc.
  • Senior Management
  • Alan R Meyer, CEO
  • Contact Info
  • Ocularis Pharma Inc.
    Phone: (708) 447-6263
    2436 S. 6th Ave.
    N. Riverside, IL 60546
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register